



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Advanced Therapy Medicinal Products: how to bring cell-based medicinal products successfully to the market

Workshop invitation

11 September 2014

Maritim Internationales Congress Centrum, Dresden, GERMANY



In collaboration with:



DEUTSCHE GESELLSCHAFT
FÜR TRANSFUSIONSMEDIZIN UND
IMMUNHÄMATOLOGIE E.V.



7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom
Telephone: +44 (0)20 7418 8400 • Facsimile +44 (0)20 7418 8416
E-mail: info@ema.europa.eu • Website: www.ema.europa.eu



An agency of the European Union

Advanced Therapy Medicinal Products

How to bring cell-based medicinal products successfully to the market

Workshop objectives

This workshop is co-organized by the European Medicines Agency's Committee for Advanced Therapies (CAT) and the German Society for Transfusion Medicine and Immunohematology (DGTI) in collaboration with the German Stem Cell Network (GSCN). The workshop aims to strengthen dialogue between CAT and the ATMP developers in industry, academia and hospitals and to facilitate ATMP development and access to the registration procedure.

The Workshop will take place on 11 September 2014 from 8³⁰–13³⁰ as a satellite symposium of the 47th DGTI Annual Meeting and will allow for the attendees of the annual meeting and for academia and industry involved in the development of ATMPs to:

- Learn about the development and authorisation of cell-based ATMPs in the EU
- Learn about role of the CAT and about the support provided by EMA and the CAT to ATMP developers
- Understand the criteria that CAT applies for the classification of ATMPs
- Hear about CAT's considerations and recent interactions with experts on cell-based therapies for cardiac repair
- Interact directly with the Regulators in an Open Forum discussion.

The workshop will be of interest to all ATMP developers: industry, including SMEs; academics from gene and cell therapy communities; healthcare professionals in the field; patient associations; regulatory professionals; corporate decision-makers; and regulators.

Programme overview

Session 1: Development and authorisation of cell-based ATMPs in the EU

Session 2: Classifications of ATMPs

Session 3: Cell-based therapies for cardiac repair

Session 4: Open forum discussion with CAT

Additional information

For further information and registration, consult the website www.dgti-kongress.de.

